MedTrace Logo

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

NCT05690191 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 169

Last updated 2023-01-19

No results posted yet for this study

Summary

A Multicenter, Prospective, Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide (cR2) in Real-world Practice in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

DRUG

Chidamide

Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses

DRUG

Lenalidomide

Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle

DRUG

Rituximab

Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle

Sponsors & Collaborators

  • Second Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Bingzong LI · Second Affiliated Hospital of Soochow University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2026-08-01
Completion
2026-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05690191 on ClinicalTrials.gov